Jean Boulle Medtech’s New Therapeutics Technology Platform Targets Trained Immunity for COVID-19 Patients and Resultant Acute Respiratory Distress Syndrome
Luxembourg, 27 April 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Medtech, is testing a unique strategy for treating Acute Respiratory Distress Syndrome 1 (“ARDS”), which could prove to be highly effective in saving the lives of COVID–19 patients.
TTxD’s proprietary platform technology is based on over a decade of research and development 2. Using bioengineering methods, TTxD produces nanobiologic therapeutics that can induce an immune response against tumors or dampen hyperinflammation after organ transplantation. TTxD has an established library of nanobiologic therapeutics relevant to many potentially fatal diseases, including ARDS.
Under an exclusive license from the Icahn School of Medicine at Mount Sinai in New York and Radboud University Medical Center in the Netherlands, TTxD applies advanced bioengineering methods to develop nanobiologic therapeutics. Nanobiologics are materials constructed from molecular building blocks that our body produces naturally. The advantage of this approach is that nanobiologic therapy ‘hijacks’ natural mechanisms to regulate the innate immune system with materials that are inherently well tolerated by the body.
Leighton Durham, Director of Jean Boulle Medtech, said:
“Our exceptional team has a unique vision and the backing of many in the global scientific community for their ground-breaking work on trained immunity and the body’s innate immune system. There is a real chance to save lives through the further development of these technologies for serious diseases, including cancer and COVID-19.”
For more information please contact:
Jean Boulle Medtech
+352 222 512
Michael Oke/Andy Mills
+44 207 321 0000
Notes to Editors:
Jean Boulle Medtech is involved in exploring and developing new technologies in a range of life saving areas of medicine:
Jean Boulle Medtech founded Tendyne Holdings, Inc., which developed the most important transcatheter mitral valve implant (“TMVI”) device in existence worldwide. Tendyne’s global success underlines Jean Boulle Medtech’s strategy as well as its valuable technical and commercial expertise. In September 2015 the Jean Boulle Group announced that an agreement had been reached for Abbott Laboratories (NYSE: ABT) (“Abbott”) to acquire Tendyne from Jean Boulle Medtech Ltd and other Tendyne shareholders for a total consideration of US$400 million excluding Abbott’s existing 10% of the company.
CE Mark approval received for Tendyne in February 2020 again highlighted the Company’s ability to invent or discover breakthrough technologies, accelerate their development, and achieve a successful exit once their potential is proven.
Jean Boulle Medtech founded VDYNE, a medical device company focused on the development of a transcatheter replacement valve to treat patients suffering from tricuspid regurgitation (“TR”). VDYNE is currently undertaking late stage pre-clinical testing and will carry out the first-in-man implant of the VDYNE valve in the first quarter of 2021.
Copyright © 2019 Jean Boulle Group. All rights reserved.